Administration of G-CSF plus dexamethasone produces greater granulocyte concentrate yields while causing no more donor toxicity than G-CSF alone
G-CSF with or without dexamethasone is becoming the standard agent for mobilizing granulocytes for transfusion. The purpose of this study was to determine if the toxicities of G--CSF with or without dexamethasone are offset by greater collection yields and to define the minimum interval that should...
Gespeichert in:
| Veröffentlicht in: | Transfusion (Philadelphia, Pa.) Pa.), 2001-08, Vol.41 (8), p.1037-1044 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1044 |
|---|---|
| container_issue | 8 |
| container_start_page | 1037 |
| container_title | Transfusion (Philadelphia, Pa.) |
| container_volume | 41 |
| creator | STRONCEK, David F YU YING YAU OBLITAS, Jaime LEITMAN, Susan F |
| description | G-CSF with or without dexamethasone is becoming the standard agent for mobilizing granulocytes for transfusion. The purpose of this study was to determine if the toxicities of G--CSF with or without dexamethasone are offset by greater collection yields and to define the minimum interval that should separate sequential collections.
Twenty donors were studied on three occasions. They were given either dexamethasone (8 mg, by mouth) plus a placebo injection, G--CSF (5 microg/kg, given subcutaneously) plus placebo capsules, or G--CSF plus dexamethasone. Granulocytes were collected by apheresis. A donor symptom survey was administered, and cell counts and blood chemistries were assessed before collection and 1, 2, 7, 14, 21, 28, and 35 days after collection.
More granulocytes were collected when G--CSF was given than when dexamethasone was given (41.1 +/- 20.4 x 10(9) vs. 21.0 +/- 10.0 x 10(9); p |
| doi_str_mv | 10.1046/j.1537-2995.2001.41081037.x |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_11493736</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>11493736</sourcerecordid><originalsourceid>FETCH-LOGICAL-p236t-28c28f42afca18d0f9ddf5dd89a2c886564187076e48cc3122182ba4b69b13533</originalsourceid><addsrcrecordid>eNpFkNFKwzAUhoMobk5fQQJ625qTpG16OYabwsAL9XpkSbpltElJWlzfwke24tSr_-L_-H7OQegOSAqE5w-HFDJWJLQss5QSAikHIoCwIj2eoelfd46mhHBIABidoKsYD4QQWhK4RBMAXrKC5VP0OdeNdTZ2QXbWO-wrvEoWr0vc1n3E2hxlY7q9jN4Z3Aave2Ui3gUjOxPGlK6vvRo6g5V3yrhvjcGDNbWO-GNv67GQfbRuh53HjQ8Ga-98wJ0_WmW7AY9yd5qU9bhyjS4qWUdzc8oZel8-vi2ekvXL6nkxXyctZXmXUKGoqDiVlZIgNKlKratMa1FKqoTIs5yDKEiRGy6UYkApCLqVfJuXW2AZYzN0--Nt-21j9KYNtpFh2Py-ZgTuT4CMStbVeKuy8Z8jxWgk7Au1AneF</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Administration of G-CSF plus dexamethasone produces greater granulocyte concentrate yields while causing no more donor toxicity than G-CSF alone</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>STRONCEK, David F ; YU YING YAU ; OBLITAS, Jaime ; LEITMAN, Susan F</creator><creatorcontrib>STRONCEK, David F ; YU YING YAU ; OBLITAS, Jaime ; LEITMAN, Susan F</creatorcontrib><description>G-CSF with or without dexamethasone is becoming the standard agent for mobilizing granulocytes for transfusion. The purpose of this study was to determine if the toxicities of G--CSF with or without dexamethasone are offset by greater collection yields and to define the minimum interval that should separate sequential collections.
Twenty donors were studied on three occasions. They were given either dexamethasone (8 mg, by mouth) plus a placebo injection, G--CSF (5 microg/kg, given subcutaneously) plus placebo capsules, or G--CSF plus dexamethasone. Granulocytes were collected by apheresis. A donor symptom survey was administered, and cell counts and blood chemistries were assessed before collection and 1, 2, 7, 14, 21, 28, and 35 days after collection.
More granulocytes were collected when G--CSF was given than when dexamethasone was given (41.1 +/- 20.4 x 10(9) vs. 21.0 +/- 10.0 x 10(9); p<0.001), but the use of G--CSF plus dexamethasone produced the greatest yields (67.1 +/- 22.0 x 10(9); p<0.002). When the donors were given dexamethasone alone, 58 percent experienced at least one symptom, compared to 85 percent of those given G--CSF and 75 percent of those given G--CSF plus dexamethasone. In all three regimens, platelet counts fell 19 percent to 24 percent after collection and remained below baseline for 7 to 14 days. Granulocyte counts returned to baseline within 3 to 7 days, but, in all three regimens, a mild granulocytopenia occurred 21 days after collection. With each of the regimens, blood chemistries changed, but the changes were mild and most returned to baseline within 7 days; however, changes in albumin, bilirubin, and AST persisted until 28 days after collection.
These results support the use of G--CSF plus dexamethasone in granulocyte donors. G--CSF plus dexamethasone resulted in greater granulocyte yields than either agent alone and was associated with donor symptoms and changes in blood cell counts and chemistries similar to those seen with G--CSF alone or dexamethasone alone. Granulocytes can be safely collected a second time after a 7-day interval; however, for regular donors, it may be best to separate collections by 4 weeks.</description><identifier>ISSN: 0041-1132</identifier><identifier>EISSN: 1537-2995</identifier><identifier>DOI: 10.1046/j.1537-2995.2001.41081037.x</identifier><identifier>PMID: 11493736</identifier><identifier>CODEN: TRANAT</identifier><language>eng</language><publisher>Oxford: Blackwell Publishing</publisher><subject>Adult ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Blood - drug effects ; Blood - metabolism ; Blood Cell Count ; Blood Component Removal ; Blood Pressure ; Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis ; Body Weight ; Dexamethasone - administration & dosage ; Dexamethasone - pharmacology ; Dexamethasone - toxicity ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Granulocyte Colony-Stimulating Factor - administration & dosage ; Granulocyte Colony-Stimulating Factor - pharmacology ; Granulocyte Colony-Stimulating Factor - toxicity ; Granulocytes - cytology ; Granulocytes - drug effects ; Hematopoietic Stem Cell Mobilization - methods ; Hematopoietic Stem Cell Mobilization - standards ; Humans ; Male ; Medical sciences ; Middle Aged ; Prospective Studies ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><ispartof>Transfusion (Philadelphia, Pa.), 2001-08, Vol.41 (8), p.1037-1044</ispartof><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1071820$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11493736$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>STRONCEK, David F</creatorcontrib><creatorcontrib>YU YING YAU</creatorcontrib><creatorcontrib>OBLITAS, Jaime</creatorcontrib><creatorcontrib>LEITMAN, Susan F</creatorcontrib><title>Administration of G-CSF plus dexamethasone produces greater granulocyte concentrate yields while causing no more donor toxicity than G-CSF alone</title><title>Transfusion (Philadelphia, Pa.)</title><addtitle>Transfusion</addtitle><description>G-CSF with or without dexamethasone is becoming the standard agent for mobilizing granulocytes for transfusion. The purpose of this study was to determine if the toxicities of G--CSF with or without dexamethasone are offset by greater collection yields and to define the minimum interval that should separate sequential collections.
Twenty donors were studied on three occasions. They were given either dexamethasone (8 mg, by mouth) plus a placebo injection, G--CSF (5 microg/kg, given subcutaneously) plus placebo capsules, or G--CSF plus dexamethasone. Granulocytes were collected by apheresis. A donor symptom survey was administered, and cell counts and blood chemistries were assessed before collection and 1, 2, 7, 14, 21, 28, and 35 days after collection.
More granulocytes were collected when G--CSF was given than when dexamethasone was given (41.1 +/- 20.4 x 10(9) vs. 21.0 +/- 10.0 x 10(9); p<0.001), but the use of G--CSF plus dexamethasone produced the greatest yields (67.1 +/- 22.0 x 10(9); p<0.002). When the donors were given dexamethasone alone, 58 percent experienced at least one symptom, compared to 85 percent of those given G--CSF and 75 percent of those given G--CSF plus dexamethasone. In all three regimens, platelet counts fell 19 percent to 24 percent after collection and remained below baseline for 7 to 14 days. Granulocyte counts returned to baseline within 3 to 7 days, but, in all three regimens, a mild granulocytopenia occurred 21 days after collection. With each of the regimens, blood chemistries changed, but the changes were mild and most returned to baseline within 7 days; however, changes in albumin, bilirubin, and AST persisted until 28 days after collection.
These results support the use of G--CSF plus dexamethasone in granulocyte donors. G--CSF plus dexamethasone resulted in greater granulocyte yields than either agent alone and was associated with donor symptoms and changes in blood cell counts and chemistries similar to those seen with G--CSF alone or dexamethasone alone. Granulocytes can be safely collected a second time after a 7-day interval; however, for regular donors, it may be best to separate collections by 4 weeks.</description><subject>Adult</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Blood - drug effects</subject><subject>Blood - metabolism</subject><subject>Blood Cell Count</subject><subject>Blood Component Removal</subject><subject>Blood Pressure</subject><subject>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</subject><subject>Body Weight</subject><subject>Dexamethasone - administration & dosage</subject><subject>Dexamethasone - pharmacology</subject><subject>Dexamethasone - toxicity</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Granulocyte Colony-Stimulating Factor - administration & dosage</subject><subject>Granulocyte Colony-Stimulating Factor - pharmacology</subject><subject>Granulocyte Colony-Stimulating Factor - toxicity</subject><subject>Granulocytes - cytology</subject><subject>Granulocytes - drug effects</subject><subject>Hematopoietic Stem Cell Mobilization - methods</subject><subject>Hematopoietic Stem Cell Mobilization - standards</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Prospective Studies</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><issn>0041-1132</issn><issn>1537-2995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkNFKwzAUhoMobk5fQQJ625qTpG16OYabwsAL9XpkSbpltElJWlzfwke24tSr_-L_-H7OQegOSAqE5w-HFDJWJLQss5QSAikHIoCwIj2eoelfd46mhHBIABidoKsYD4QQWhK4RBMAXrKC5VP0OdeNdTZ2QXbWO-wrvEoWr0vc1n3E2hxlY7q9jN4Z3Aave2Ui3gUjOxPGlK6vvRo6g5V3yrhvjcGDNbWO-GNv67GQfbRuh53HjQ8Ga-98wJ0_WmW7AY9yd5qU9bhyjS4qWUdzc8oZel8-vi2ekvXL6nkxXyctZXmXUKGoqDiVlZIgNKlKratMa1FKqoTIs5yDKEiRGy6UYkApCLqVfJuXW2AZYzN0--Nt-21j9KYNtpFh2Py-ZgTuT4CMStbVeKuy8Z8jxWgk7Au1AneF</recordid><startdate>20010801</startdate><enddate>20010801</enddate><creator>STRONCEK, David F</creator><creator>YU YING YAU</creator><creator>OBLITAS, Jaime</creator><creator>LEITMAN, Susan F</creator><general>Blackwell Publishing</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20010801</creationdate><title>Administration of G-CSF plus dexamethasone produces greater granulocyte concentrate yields while causing no more donor toxicity than G-CSF alone</title><author>STRONCEK, David F ; YU YING YAU ; OBLITAS, Jaime ; LEITMAN, Susan F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p236t-28c28f42afca18d0f9ddf5dd89a2c886564187076e48cc3122182ba4b69b13533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Blood - drug effects</topic><topic>Blood - metabolism</topic><topic>Blood Cell Count</topic><topic>Blood Component Removal</topic><topic>Blood Pressure</topic><topic>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</topic><topic>Body Weight</topic><topic>Dexamethasone - administration & dosage</topic><topic>Dexamethasone - pharmacology</topic><topic>Dexamethasone - toxicity</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Granulocyte Colony-Stimulating Factor - administration & dosage</topic><topic>Granulocyte Colony-Stimulating Factor - pharmacology</topic><topic>Granulocyte Colony-Stimulating Factor - toxicity</topic><topic>Granulocytes - cytology</topic><topic>Granulocytes - drug effects</topic><topic>Hematopoietic Stem Cell Mobilization - methods</topic><topic>Hematopoietic Stem Cell Mobilization - standards</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Prospective Studies</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>STRONCEK, David F</creatorcontrib><creatorcontrib>YU YING YAU</creatorcontrib><creatorcontrib>OBLITAS, Jaime</creatorcontrib><creatorcontrib>LEITMAN, Susan F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Transfusion (Philadelphia, Pa.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>STRONCEK, David F</au><au>YU YING YAU</au><au>OBLITAS, Jaime</au><au>LEITMAN, Susan F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Administration of G-CSF plus dexamethasone produces greater granulocyte concentrate yields while causing no more donor toxicity than G-CSF alone</atitle><jtitle>Transfusion (Philadelphia, Pa.)</jtitle><addtitle>Transfusion</addtitle><date>2001-08-01</date><risdate>2001</risdate><volume>41</volume><issue>8</issue><spage>1037</spage><epage>1044</epage><pages>1037-1044</pages><issn>0041-1132</issn><eissn>1537-2995</eissn><coden>TRANAT</coden><abstract>G-CSF with or without dexamethasone is becoming the standard agent for mobilizing granulocytes for transfusion. The purpose of this study was to determine if the toxicities of G--CSF with or without dexamethasone are offset by greater collection yields and to define the minimum interval that should separate sequential collections.
Twenty donors were studied on three occasions. They were given either dexamethasone (8 mg, by mouth) plus a placebo injection, G--CSF (5 microg/kg, given subcutaneously) plus placebo capsules, or G--CSF plus dexamethasone. Granulocytes were collected by apheresis. A donor symptom survey was administered, and cell counts and blood chemistries were assessed before collection and 1, 2, 7, 14, 21, 28, and 35 days after collection.
More granulocytes were collected when G--CSF was given than when dexamethasone was given (41.1 +/- 20.4 x 10(9) vs. 21.0 +/- 10.0 x 10(9); p<0.001), but the use of G--CSF plus dexamethasone produced the greatest yields (67.1 +/- 22.0 x 10(9); p<0.002). When the donors were given dexamethasone alone, 58 percent experienced at least one symptom, compared to 85 percent of those given G--CSF and 75 percent of those given G--CSF plus dexamethasone. In all three regimens, platelet counts fell 19 percent to 24 percent after collection and remained below baseline for 7 to 14 days. Granulocyte counts returned to baseline within 3 to 7 days, but, in all three regimens, a mild granulocytopenia occurred 21 days after collection. With each of the regimens, blood chemistries changed, but the changes were mild and most returned to baseline within 7 days; however, changes in albumin, bilirubin, and AST persisted until 28 days after collection.
These results support the use of G--CSF plus dexamethasone in granulocyte donors. G--CSF plus dexamethasone resulted in greater granulocyte yields than either agent alone and was associated with donor symptoms and changes in blood cell counts and chemistries similar to those seen with G--CSF alone or dexamethasone alone. Granulocytes can be safely collected a second time after a 7-day interval; however, for regular donors, it may be best to separate collections by 4 weeks.</abstract><cop>Oxford</cop><pub>Blackwell Publishing</pub><pmid>11493736</pmid><doi>10.1046/j.1537-2995.2001.41081037.x</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0041-1132 |
| ispartof | Transfusion (Philadelphia, Pa.), 2001-08, Vol.41 (8), p.1037-1044 |
| issn | 0041-1132 1537-2995 |
| language | eng |
| recordid | cdi_pubmed_primary_11493736 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Adult Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Blood - drug effects Blood - metabolism Blood Cell Count Blood Component Removal Blood Pressure Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis Body Weight Dexamethasone - administration & dosage Dexamethasone - pharmacology Dexamethasone - toxicity Double-Blind Method Drug Therapy, Combination Female Granulocyte Colony-Stimulating Factor - administration & dosage Granulocyte Colony-Stimulating Factor - pharmacology Granulocyte Colony-Stimulating Factor - toxicity Granulocytes - cytology Granulocytes - drug effects Hematopoietic Stem Cell Mobilization - methods Hematopoietic Stem Cell Mobilization - standards Humans Male Medical sciences Middle Aged Prospective Studies Transfusions. Complications. Transfusion reactions. Cell and gene therapy |
| title | Administration of G-CSF plus dexamethasone produces greater granulocyte concentrate yields while causing no more donor toxicity than G-CSF alone |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T19%3A37%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Administration%20of%20G-CSF%20plus%20dexamethasone%20produces%20greater%20granulocyte%20concentrate%20yields%20while%20causing%20no%20more%20donor%20toxicity%20than%20G-CSF%20alone&rft.jtitle=Transfusion%20(Philadelphia,%20Pa.)&rft.au=STRONCEK,%20David%20F&rft.date=2001-08-01&rft.volume=41&rft.issue=8&rft.spage=1037&rft.epage=1044&rft.pages=1037-1044&rft.issn=0041-1132&rft.eissn=1537-2995&rft.coden=TRANAT&rft_id=info:doi/10.1046/j.1537-2995.2001.41081037.x&rft_dat=%3Cpubmed_pasca%3E11493736%3C/pubmed_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/11493736&rfr_iscdi=true |